Rocket


News + Filings
Key Docs
Charts
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

ONCOLYTICS BIOTECH INC (ONCY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Inc. June 30, 2023 Interim Financial Statements",
"Oncolytics Biotech® Inc. June 30, 2023 Management Discussion & Analysis",
"Certification of June 30, 2023 interim filings - CEO",
"Certification of June 30, 2023 interim filings - CFO"
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression"
08/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 43rd Annual Growth Conference"
08/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET"
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET"
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"May 9, 2023 AGM Voting Results"
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders"
05/05/2023 6-K Quarterly results
05/05/2023 6-K Quarterly results
04/26/2023 6-K Quarterly results
04/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Information Circular",
"Form of Proxy"
03/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients"
12/08/2022 6-K Quarterly results
12/01/2022 6-K Quarterly results
11/21/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights Clinical interim data reported earlier today from GOBLET trial’s pancreatic cancer cohort show an objective response rate nearly triple the average ORR seen in relevant historical control trials"
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Inc. September 30, 2022 Interim Financial Statements",
"Oncolytics Biotech® Inc. September 30, 2022 Management Discussion & Analysis",
"Certification of September 30, 2022 interim filings - CEO",
"Certification of September 30, 2022 interim filings - CFO"
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting 70% objective response rate is nearly triple the average ORR of ~25% reported in historical control trials1-4"
10/27/2022 6-K Quarterly results
10/05/2022 6-K Quarterly results
09/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries"
08/11/2022 6-K Quarterly results
08/11/2022 6-K Quarterly results
07/27/2022 6-K Quarterly results
06/28/2022 6-K Quarterly results
06/17/2022 6-K Quarterly results
06/17/2022 6-K Quarterly results
05/17/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
05/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "2022 FIRST QUARTER 6-K",
"Oncolytics Biotech® Inc. March 31, 2022 Interim Financial Statements",
"Oncolytics Biotech® Inc. March 31, 2022 Management Discussion & Analysis",
"Certification of March 31, 2022 interim filings - CEO",
"Certification of March 31, 2022 interim filings - CFO"
05/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial"
05/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting Pelareorep treatment resulted in a favorable Risk of Recurrence Score in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study"
05/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy